vs
Side-by-side financial comparison of BayCom Corp (BCML) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $25.9M, roughly 1.1× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -147.1%, a 173.6% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -67.6%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
BCML vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $28.1M |
| Net Profit | $6.9M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -147.6% |
| Net Margin | 26.5% | -147.1% |
| Revenue YoY | 9.4% | -67.6% |
| Net Profit YoY | 12.1% | -182.8% |
| EPS (diluted) | $0.63 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $28.1M | ||
| Q3 25 | $25.7M | $32.5M | ||
| Q2 25 | $24.7M | $15.7M | ||
| Q1 25 | $24.3M | $8.0M | ||
| Q4 24 | $23.7M | $86.6M | ||
| Q3 24 | $25.6M | $2.1M | ||
| Q2 24 | $23.8M | $500.0K | ||
| Q1 24 | $24.5M | $0 |
| Q4 25 | $6.9M | $-41.3M | ||
| Q3 25 | $5.0M | $-51.2M | ||
| Q2 25 | $6.4M | $-44.9M | ||
| Q1 25 | $5.7M | $-33.9M | ||
| Q4 24 | $6.1M | $49.9M | ||
| Q3 24 | $6.0M | $-19.1M | ||
| Q2 24 | $5.6M | $-12.5M | ||
| Q1 24 | $5.9M | $-10.3M |
| Q4 25 | 36.6% | -147.6% | ||
| Q3 25 | 26.3% | -163.7% | ||
| Q2 25 | 35.3% | -302.9% | ||
| Q1 25 | 31.6% | -466.3% | ||
| Q4 24 | 34.2% | 54.5% | ||
| Q3 24 | 32.4% | -1051.6% | ||
| Q2 24 | 31.9% | -3068.0% | ||
| Q1 24 | 33.3% | — |
| Q4 25 | 26.5% | -147.1% | ||
| Q3 25 | 19.5% | -157.4% | ||
| Q2 25 | 25.8% | -285.6% | ||
| Q1 25 | 23.4% | -425.7% | ||
| Q4 24 | 25.9% | 57.7% | ||
| Q3 24 | 23.5% | -925.0% | ||
| Q2 24 | 23.6% | -2503.2% | ||
| Q1 24 | 24.0% | — |
| Q4 25 | $0.63 | $-0.41 | ||
| Q3 25 | $0.46 | $-0.52 | ||
| Q2 25 | $0.58 | $-0.46 | ||
| Q1 25 | $0.51 | $-0.35 | ||
| Q4 24 | $0.55 | $0.52 | ||
| Q3 24 | $0.54 | $-0.20 | ||
| Q2 24 | $0.50 | $-0.13 | ||
| Q1 24 | $0.51 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $338.6M | $114.3M |
| Total Assets | $2.6B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $338.6M | $114.3M | ||
| Q3 25 | $334.3M | $147.7M | ||
| Q2 25 | $330.6M | $192.3M | ||
| Q1 25 | $329.3M | $229.0M | ||
| Q4 24 | $324.4M | $256.8M | ||
| Q3 24 | $321.7M | $201.0M | ||
| Q2 24 | $315.3M | $215.2M | ||
| Q1 24 | $314.2M | $223.9M |
| Q4 25 | $2.6B | $327.7M | ||
| Q3 25 | $2.6B | $372.8M | ||
| Q2 25 | $2.6B | $313.5M | ||
| Q1 25 | $2.6B | $327.3M | ||
| Q4 24 | $2.7B | $351.2M | ||
| Q3 24 | $2.6B | $217.6M | ||
| Q2 24 | $2.6B | $222.0M | ||
| Q1 24 | $2.6B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-43.5M |
| Free Cash FlowOCF − Capex | $30.1M | — |
| FCF MarginFCF / Revenue | 116.2% | — |
| Capex IntensityCapex / Revenue | 6.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-43.5M | ||
| Q3 25 | $7.3M | $-47.0M | ||
| Q2 25 | $6.4M | $-39.6M | ||
| Q1 25 | $9.3M | $-40.7M | ||
| Q4 24 | $30.4M | $42.0M | ||
| Q3 24 | $9.6M | $-14.5M | ||
| Q2 24 | $7.7M | $-7.3M | ||
| Q1 24 | $5.1M | $-6.7M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | $-47.2M | ||
| Q2 25 | $5.6M | $-39.6M | ||
| Q1 25 | $9.1M | $-40.8M | ||
| Q4 24 | $28.7M | $41.7M | ||
| Q3 24 | $9.4M | $-14.6M | ||
| Q2 24 | $7.4M | $-7.3M | ||
| Q1 24 | $3.9M | $-6.8M |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | -145.4% | ||
| Q2 25 | 22.8% | -252.2% | ||
| Q1 25 | 37.6% | -512.1% | ||
| Q4 24 | 121.1% | 48.2% | ||
| Q3 24 | 36.6% | -706.3% | ||
| Q2 24 | 31.2% | -1463.4% | ||
| Q1 24 | 16.1% | — |
| Q4 25 | 6.7% | 0.0% | ||
| Q3 25 | 4.3% | 0.6% | ||
| Q2 25 | 3.0% | 0.3% | ||
| Q1 25 | 0.6% | 1.1% | ||
| Q4 24 | 7.2% | 0.3% | ||
| Q3 24 | 1.0% | 6.8% | ||
| Q2 24 | 1.0% | 7.6% | ||
| Q1 24 | 4.7% | — |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | 0.84× | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
